TP53 and prostate carcinoma: Goserelin, a GnRH-I agonist, has been demonstrated to increase the expression of the proapoptotic protein B-cell CLL/lymphoma 2 (BCL2)-associated X protein (BAX) in a TP53-dependent manner in a prostate cancer cell line [28], while in the case of ovarian cell lines, this analog could upregulate several members of tumor necrosis factor (TNF) and TNF-receptor superfamilies through the Forkhead Box O1–Phosphoinositide-3-Kinase–v-akt murine thymoma viral oncogene homolog (AKT) pathway [29].